Novartis Lowers Price for Lucentis Drug By 30 Percent, AWP Says
This article is for subscribers only.
Novartis AG will lower the price of its Lucentis drug by 30 percent following pressure from Swiss authorities, Swiss news agency AWP said, citing Le Matin newspaper.
The reduction will also affect prices outside Switzerland as they are derived from prices in the country, AWP said, citing Novartis’s press office.